Furthermore, METTL3 downregulation in CMLs reduced its ability to modify NETA1 m6A, subsequently enhancing CML cell viability and inhibiting CML cell apoptosis. Here, METTL3 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.